Transverse Medical
Denver, CO · Healthcare, Other · 9 employees
Transverse Medical Inc. (TMI) is developing the POINT-GUARD™ Cerebral Embolic Protection (CEP) medical device to address the unmet need for Full Brain Protection and the clinical problem of periprocedural Stroke in Structural Heart Procedures, such as Transcatheter Aortic Valve Replacement (TAVR).
Funding history
- Series B — $10.0M — Apr 2025
- Venture - Series Unknown — $10.0M — Dec 2024
- Venture - Series Unknown — $6.6M — Aug 2023
- Pre-Seed — $140K — Nov 2019
- Venture - Series Unknown — $7.8M — Oct 2018
Recent signals
- Jun 03, 2026: Transverse Medical Appoints Thomas E. Chilcott as Chief Financial Officer
- Apr 29, 2025: Raised $10.0M in Series B
- Dec 10, 2024: Raised $10.0M in Venture - Series Unknown
- Aug 18, 2023: Raised $6.6M in Venture - Series Unknown
- Nov 21, 2019: Raised $140K in Pre-Seed
- Oct 03, 2018: Raised $7.8M in Venture - Series Unknown
- May 24, 2017: Raised Undisclosed in Venture - Series Unknown
See plans & pricing → Track Transverse Medical’s funding, hiring, and signals — with verified contacts — on Fundz.